このレポートは、適応症別（乾癬、乾癬性関節炎、強直性脊椎炎）、薬剤別（セクキヌマブ、イクキズマブ、ビメキズマブ、ブロダルマブ）、地域別、国別の市場セグメンテーションの観点から、世界のIL-17生物製剤業界の完全な分析を提供します。データは 2022 年、2023 年の推計、および 2024 年から 2030 年の予測期間について示されています。
この調査レポートには、地域（南北アメリカ、ヨーロッパ、APAC）および 9カ国（アメリカ、カナダ、イギリス、ドイツ、フランス、スペイン、中国、日本、オーストラリア）の詳細な分析が含まれています。 さらに、調査レポートには、市場規模、年間成長と潜在力の分析、市場プレーヤーの競合調査、投資機会、需要予測などのデータが示されています。
この調査レポートはまた、成長指標、抑制要因、需給リスク、その他の重要な統計を評価するだけでなく、市場の進化に関連する現在および将来の市場動向の完全な評価も行っています。
世界のIL-17生物製剤市場は、2022年の43億7,000万米ドルから2030年末までに109億米ドルを生み出すと予想されています。世界のIL-17生物製剤市場にとって好ましい成長要素は、自己免疫疾患や炎症性疾患の有病率の増加、これらの症状の管理におけるこれらの薬剤の有効性、および革新的な治療法の需要です。2024年から2030年の予測期間中に、世界のIL-17生物製剤は12.3%のCAGRで拡大すると予想されます。財政支援、教育リソース、医療専門家へのアクセスなどの患者支援プログラムの実施により、IL-17 生物製剤に対する患者のアドヒアランスと全体的な満足度が向上しました。これらのプログラムは、治療を確実に成功させる上で極めて重要です。
国立幹細胞財団によると、世界人口の約4%が80以上の異なる自己免疫疾患のいずれかに罹患しています。自己免疫疾患は、米国における慢性疾患の原因として3番目に多いものです。理由は不明ですが、自己免疫疾患の有病率が増加しています。これらの自己免疫疾患におけるIL-1阻害薬の使用は、免疫系の調節不全や炎症を特徴とするさまざまな状態の管理におけるこのクラスの生物学的製剤の多用途性と可能性を反映しています。
モノクローナル抗体工学の進歩により、高度に標的を絞ったIL-17生物製剤の開発が行われました。抗体のヒト化や親和性成熟などの技術は、副作用を軽減した、より効果的で特異的な生物製剤の作成に役立ちます。
IL-17生物製剤の長期的な安全性と有効性を確保するために、これらの治療に対する免疫反応を監視および管理するための革新的な免疫原性試験方法が開発されました。これらの検査は、抗薬物抗体の発生を検出し、それによって治療効果を維持する上で重要な役割を果たします。技術の進歩により、IL-17生物製剤用の革新的なドラッグデリバリーシステムの開発が行われました。たとえば、自己注射器は患者の自己投与を容易にするために作られています。Cosentyx（セクキヌマブ）はプレフィルドシリンジまたは自動注射器で入手できるため、患者の利便性が向上します。
IL-17生物製剤の市場は、これらの薬剤が追加の自己免疫疾患適応症に対する規制当局の承認を受けているため、拡大しています。たとえば、セクキヌマブは当初、乾癬の治療薬として承認され、その後、強直性脊椎炎および乾癬性関節炎に対しても承認され、市場の可能性が広がりました。適応症の増加により、IL-17生物学的製剤の適応となる患者数が増加します。
目次
Table of Contents
1. Market Background
1.1 Scope and Product Outlook
1.2 Executive Summary
1.3 Research Methodology
2. Strategic Recommendations
3. Global IL-17 Biologics Market Assessment
3.1 Impact Analysis of Macro Economic Factors on Global IL-17 Biologics Market
3.2 Epidemiology
3.3 Pipeline Development of IL-17 Biologics
3.4 Global IL-17 Biologics Market: Market Size and CAGR, 2022-2030 (USD Million & CAGR)
3.5 Degree of Impact of Covid-19 on IL-17 Biologics Market
3.6 Global IL-17 Biologics Market Segmentation: By Indication
3.6.1 Global IL-17 Biologics Market, By Indication Overview
3.6.2 Global IL-17 Biologics Market Size, By Psoriasis, By Value, 2022A-2030F (USD Million & CAGR)
3.6.3 Global IL-17 Biologics Market Size, By Psoriatic Arthritis, By Value, 2022A-2030F (USD Million & CAGR)
3.6.4 Global IL-17 Biologics Market Size, By Ankylosing Spondylitis, By Value, 2022A-2030F (USD Million & CAGR)
3.7 Global IL-17 Biologics Market Segmentation: By Drug
3.7.1 Global IL-17 Biologics Market, By Drug Overview
3.7.2 Global IL-17 Biologics Market Size, By Secukinumab, By Value, 2022A-2030F (USD Million & CAGR)
3.7.3 Global IL-17 Biologics Market Size, By Ixekizumab, By Value, 2022A-2030F (USD Million & CAGR)
3.7.4 Global IL-17 Biologics Market Size, By Bimekizumab, By Value, 2022A-2030F (USD Million & CAGR)
3.7.5 Global IL-17 Biologics Market Size, By Brodalumab, By Value, 2022A-2030F (USD Million & CAGR)
4. Global IL-17 Biologics Market, Regional Analysis
4.1 Regional Coverage of the Study
4.2 Regional Snapshot
5. Americas IL-17 Biologics Market Assessment (2022-2030)
5.1 Americas IL-17 Biologics Market: Snapshot
5.2 Americas IL-17 Biologics Market: Market Size and CAGR, 2022-2030 (USD Million & CAGR)
5.3 Americas IL-17 Biologics Market: Key Factors
5.4 Americas IL-17 Biologics Market: Segment Analysis
5.5 Americas IL-17 Biologics Market Segmentation: By Indication
5.5.1 Americas IL-17 Biologics Market, By Indication Overview
5.5.2 Americas IL-17 Biologics Market Size, By Psoriasis, By Value, 2022A-2030F (USD Million & CAGR)
5.5.3 Americas IL-17 Biologics Market Size, By Psoriatic Arthritis, By Value, 2022A-2030F (USD Million & CAGR)
5.5.4 Americas IL-17 Biologics Market Size, By Ankylosing Spondylitis, By Value, 2022A-2030F (USD Million & CAGR)
5.6 Americas IL-17 Biologics Market Segmentation: By Drug
5.6.1 Americas IL-17 Biologics Market, By Drug Overview
5.6.2 Americas IL-17 Biologics Market Size, By Secukinumab, By Value, 2022A-2030F (USD Million & CAGR)
5.6.3 Americas IL-17 Biologics Market Size, By Ixekizumab, By Value, 2022A-2030F (USD Million & CAGR)
5.6.4 Americas IL-17 Biologics Market Size, By Bimekizumab, By Value, 2022A-2030F (USD Million & CAGR)
5.6.5 Americas IL-17 Biologics Market Size, By Brodalumab, By Value, 2022A-2030F (USD Million & CAGR)
5.7 Americas IL-17 Biologics Market Segmentation: By Country
5.7.1 Americas IL-17 Biologics Market, By Country Overview
5.7.2 United States IL-17 Biologics Market: Market Size and CAGR, 2022-2030 (USD Million & CAGR)
5.7.2.1 United States IL-17 Biologics Market, By Indication
5.7.2.2 United States IL-17 Biologics Market, By Drug
5.7.3 Canada IL-17 Biologics Market: Market Size and CAGR, 2022-2030 (USD Million & CAGR)
5.7.3.1 Canada IL-17 Biologics Market, By Indication
5.7.3.2 Canada IL-17 Biologics Market, By Drug
5.7.4 Rest of Americas IL-17 Biologics Market: Market Size and CAGR, 2022-2030 (USD Million & CAGR)
5.7.4.1 Rest of Americas IL-17 Biologics Market, By Indication
5.7.4.2 Rest of Americas IL-17 Biologics Market, By Drug
6. Europe IL-17 Biologics Market Assessment (2022-2030)
6.1 Europe IL-17 Biologics Market: Snapshot
6.2 Europe IL-17 Biologics Market: Market Size and CAGR, 2022-2030 (USD Million & CAGR)
6.3 Europe IL-17 Biologics Market: Key Factors
6.4 Europe IL-17 Biologics Market: Segment Analysis
6.5 Europe IL-17 Biologics Market Segmentation: By Indication
6.5.1 Europe IL-17 Biologics Market, By Indication Overview
6.5.2 Europe IL-17 Biologics Market Size, By Psoriasis, By Value, 2022A-2030F (USD Million & CAGR)
6.5.3 Europe IL-17 Biologics Market Size, By Psoriatic Arthritis, By Value, 2022A-2030F (USD Million & CAGR)
6.5.4 Europe IL-17 Biologics Market Size, By Ankylosing Spondylitis, By Value, 2022A-2030F (USD Million & CAGR)
6.6 Europe IL-17 Biologics Market Segmentation: By Drug
6.6.1 Europe IL-17 Biologics Market, By Drug Overview
6.6.2 Europe IL-17 Biologics Market Size, By Secukinumab, By Value, 2022A-2030F (USD Million & CAGR)
6.6.3 Europe IL-17 Biologics Market Size, By Ixekizumab, By Value, 2022A-2030F (USD Million & CAGR)
6.6.4 Europe IL-17 Biologics Market Size, By Bimekizumab, By Value, 2022A-2030F (USD Million & CAGR)
6.6.5 Europe IL-17 Biologics Market Size, By Brodalumab, By Value, 2022A-2030F (USD Million & CAGR)
6.7 Europe IL-17 Biologics Market Segmentation: By Country
6.7.1 Europe IL-17 Biologics Market, By Country Overview
6.7.2 Germany IL-17 Biologics Market: Market Size and CAGR, 2022-2030 (USD Million & CAGR)
6.7.2.1 Germany IL-17 Biologics Market, By Indication
6.7.2.2 Germany IL-17 Biologics Market, By Drug
6.7.3 United Kingdom IL-17 Biologics Market: Market Size and CAGR, 2022-2030 (USD Million & CAGR)
6.7.3.1 United Kingdom IL-17 Biologics Market, By Indication
6.7.3.2 United Kingdom IL-17 Biologics Market, By Drug
6.7.4 France IL-17 Biologics Market: Market Size and CAGR, 2022-2030 (USD Million & CAGR)
6.7.4.1 France IL-17 Biologics Market, By Indication
6.7.4.2 France IL-17 Biologics Market, By Drug
6.7.5 Spain IL-17 Biologics Market: Market Size and CAGR, 2022-2030 (USD Million & CAGR)
6.7.5.1 Spain IL-17 Biologics Market, By Indication
6.7.5.2 Spain IL-17 Biologics Market, By Drug
6.7.6 Rest of Europe IL-17 Biologics Market: Market Size and CAGR, 2022-2030 (USD Million & CAGR)
6.7.6.1 Rest of Europe IL-17 Biologics Market, By Indication
6.7.6.2 Rest of Europe IL-17 Biologics Market, By Drug
7. Asia Pacific IL-17 Biologics Market Assessment (2022-2030)
7.1 Asia Pacific IL-17 Biologics Market: Snapshot
7.2 Asia Pacific IL-17 Biologics Market: Market Size and CAGR, 2022-2030 (USD Million & CAGR)
7.3 Asia Pacific IL-17 Biologics Market: Key Factors
7.4 Asia Pacific IL-17 Biologics Market: Segment Analysis
7.5 Asia Pacific IL-17 Biologics Market Segmentation: By Indication
7.5.1 Asia Pacific IL-17 Biologics Market, By Indication Overview
7.5.2 Asia Pacific IL-17 Biologics Market Size, By Psoriasis, By Value, 2022A-2030F (USD Million & CAGR)
7.5.3 Asia Pacific IL-17 Biologics Market Size, By Psoriatic Arthritis, By Value, 2022A-2030F (USD Million & CAGR)
7.5.4 Asia Pacific IL-17 Biologics Market Size, By Ankylosing Spondylitis, By Value, 2022A-2030F (USD Million & CAGR)
7.6 Asia Pacific IL-17 Biologics Market Segmentation: By Drug
7.6.1 Asia Pacific IL-17 Biologics Market, By Drug Overview
7.6.2 Asia Pacific IL-17 Biologics Market Size, By Secukinumab, By Value, 2022A-2030F (USD Million & CAGR)
7.6.3 Asia Pacific IL-17 Biologics Market Size, By Ixekizumab, By Value, 2022A-2030F (USD Million & CAGR)
7.6.4 Asia Pacific IL-17 Biologics Market Size, By Bimekizumab, By Value, 2022A-2030F (USD Million & CAGR)
7.6.5 Asia Pacific IL-17 Biologics Market Size, By Brodalumab, By Value, 2022A-2030F (USD Million & CAGR)
7.7 Asia Pacific IL-17 Biologics Market Segmentation: By Country
7.7.1 Asia Pacific IL-17 Biologics Market, By Country Overview
7.7.2 China IL-17 Biologics Market: Market Size and CAGR, 2022-2030 (USD Million & CAGR)
7.7.2.1 China IL-17 Biologics Market, By Indication
7.7.2.2 China IL-17 Biologics Market, By Drug
7.7.3 Japan IL-17 Biologics Market: Market Size and CAGR, 2022-2030 (USD Million & CAGR)
7.7.3.1 Japan IL-17 Biologics Market, By Indication
7.7.3.2 Japan IL-17 Biologics Market, By Drug
7.7.4 Australia IL-17 Biologics Market: Market Size and CAGR, 2022-2030 (USD Million & CAGR)
7.7.4.1 Australia IL-17 Biologics Market, By Indication
7.7.4.2 Australia IL-17 Biologics Market, By Drug
7.7.5 Rest of Asia Pacific IL-17 Biologics Market: Market Size and CAGR, 2022-2030 (USD Million & CAGR)
7.7.5.1 Rest of Asia Pacific IL-17 Biologics Market, By Indication
7.7.5.2 Rest of Asia Pacific IL-17 Biologics Market, By Drug
8. Market Dynamics
8.1 Impact Assessment of Market Dynamics on Global IL-17 Biologics Market
8.2 Drivers
8.3 Restraints
8.4 Trends
9. Industry Ecosystem Analysis
9.1 Porter Analysis
10. Competitive Positioning
10.1 Companies’ Product Positioning
10.2 Market Share of Leading Companies
10.3 Company Profiling
10.3.1 Novartis
10.3.2 Eli Lilly and Company
10.3.3 UCB
10.3.4 AstraZeneca PLC
List of Figures
Figure 1: Global IL-17 Biologics Market Size, By Value, 2022A-2030F (USD Million)
Figure 2: Global IL-17 Biologics Market Share, By Drug, 2022 (%)
Figure 3: Global IL-17 Biologics Market Size, By Psoriasis, By Value, 2022A-2030F (USD Million & CAGR)
Figure 4: Global IL-17 Biologics Market Absolute Opportunity, By Psoriasis, 2022A-2030F (USD Million)
Figure 5: Global IL-17 Biologics Market Size, By Psoriatic Arthritis, By Value, 2022A-2030F (USD Million & CAGR)
Figure 6: Global IL-17 Biologics Market Absolute Opportunity, By Psoriatic Arthritis, 2022A-2030F (USD Million)
Figure 7: Global IL-17 Biologics Market Size, By Ankylosing Spondylitis, By Value, 2022A-2030F (USD Million & CAGR)
Figure 8: Global IL-17 Biologics Market Absolute Opportunity, By Ankylosing Spondylitis, 2022A-2030F (USD Million)
Figure 9: Global IL-17 Biologics Market Size, By Secukinumab, By Value, 2022A-2030F (USD Million & CAGR)
Figure 10: Global IL-17 Biologics Market Absolute Opportunity, By Secukinumab, 2022A-2030F (USD Million)
Figure 11: Global IL-17 Biologics Market Size, By Ixekizumab, By Value, 2022A-2030F (USD Million & CAGR)
Figure 12: Global IL-17 Biologics Market Absolute Opportunity, By Ixekizumab , 2022A-2030F (USD Million)
Figure 13: Global IL-17 Biologics Market Size, By Bimekizumab, By Value, 2022A-2030F (USD Million & CAGR)
Figure 14: Global IL-17 Biologics Market Absolute Opportunity, By Bimekizumab, 2022A-2030F (USD Million)
Figure 15: Global IL-17 Biologics Market Size, By Brodalumab, By Value, 2022A-2030F (USD Million & CAGR)
Figure 16: Global IL-17 Biologics Market Absolute Opportunity, By Brodalumab, 2022A-2030F (USD Million)
Figure 17: Americas IL-17 Biologics Market Size, By Value, 2022A-2030F (USD Million)
Figure 18: Americas IL-17 Biologics Market Share, By Drug, 2022 (%)
Figure 19: Americas IL-17 Biologics Market, By Psoriasis, By Value, 2022A-2030F (USD Million & CAGR)
Figure 20: Americas IL-17 Biologics Market, By Psoriatic Arthritis, By Value, 2022A-2030F (USD Million & CAGR)
Figure 21: Americas IL-17 Biologics Market, By Ankylosing Spondylitis, By Value, 2022A-2030F (USD Million & CAGR)
Figure 22: Americas IL-17 Biologics Market, By Secukinumab, By Value, 2022A-2030F (USD Million & CAGR)
Figure 23: Americas IL-17 Biologics Market, By Ixekizumab, By Value, 2022A-2030F (USD Million & CAGR)
Figure 24: Americas IL-17 Biologics Market, By Bimekizumab, By Value, 2022A-2030F (USD Million & CAGR)
Figure 25: Americas IL-17 Biologics Market, By Brodalumab, By Value, 2022A-2030F (USD Million & CAGR)
Figure 26: United States IL-17 Biologics Market, By Value, 2022A-2030F (USD Million & CAGR)
Figure 27: United States IL-17 Biologics Market Value, By Indication, 2022 (USD Million)
Figure 28: United States IL-17 Biologics Market Share, By Indication, By Value, 2022 (%)
Figure 29: United States IL-17 Biologics Market, By Indication, By Value, 2022A-2030F (USD Million)
Figure 30: United States IL-17 Biologics Market Share, By Drug, By Value, 2022 (%)
Figure 31: United States IL-17 Biologics Market, By Drug, By Value, 2022A-2030F (USD Million)
Figure 32: Canada IL-17 Biologics Market, By Value, 2022A-2030F (USD Million & CAGR)
Figure 33: Canada IL-17 Biologics Market Value, By Indication, 2022 (USD Million)
Figure 34: Canada IL-17 Biologics Market Share, By Indication, By Value, 2022 (%)
Figure 35: Canada IL-17 Biologics Market, By Indication, By Value, 2022A-2030F (USD Million)
Figure 36: Canada IL-17 Biologics Market Share, By Drug, By Value, 2022 (%)
Figure 37: Canada IL-17 Biologics Market, By Drug, By Value, 2022A-2030F (USD Million)
Figure 38: Rest of Americas IL-17 Biologics Market , By Value, 2022A-2030F (USD Million & CAGR)
Figure 39: Rest of Americas IL-17 Biologics Market Value, By Indication, 2022 (USD Million)
Figure 40: Rest of Americas IL-17 Biologics Market Share, By Indication, By Value, 2022 (%)
Figure 41: Rest of Americas IL-17 Biologics Market , By Indication, By Value, 2022A-2030F (USD Million)
Figure 42: Rest of Americas IL-17 Biologics Market Share, By Drug, By Value, 2022 (%)
Figure 43: Rest of Americas IL-17 Biologics Market , By Drug, By Value, 2022A-2030F (USD Million)
Figure 44: Europe IL-17 Biologics Market Size, By Value, 2022A-2030F (USD Million)
Figure 45: Europe IL-17 Biologics Market Share, By Drug, 2022 (%)
Figure 46: Europe IL-17 Biologics Market, By Psoriasis, By Value, 2022A-2030F (USD Million & CAGR)
Figure 47: Europe IL-17 Biologics Market, By Psoriatic Arthritis, By Value, 2022A-2030F (USD Million & CAGR)
Figure 48: Europe IL-17 Biologics Market, By Ankylosing Spondylitis, By Value, 2022A-2030F (USD Million & CAGR)
Figure 49: Europe IL-17 Biologics Market, By Secukinumab, By Value, 2022A-2030F (USD Million & CAGR)
Figure 50: Europe IL-17 Biologics Market, By Ixekizumab, By Value, 2022A-2030F (USD Million & CAGR)
Figure 51: Europe IL-17 Biologics Market, By Bimekizumab, By Value, 2022A-2030F (USD Million & CAGR)
Figure 52: Europe IL-17 Biologics Market, By Brodalumab, By Value, 2022A-2030F (USD Million & CAGR)
Figure 53: Germany IL-17 Biologics Market, By Value, 2022A-2030F (USD Million & CAGR)
Figure 54: Germany IL-17 Biologics Market Value, By Indication, 2022 (USD Million)
Figure 55: Germany IL-17 Biologics Market Share, By Indication, By Value, 2022 (%)
Figure 56: Germany IL-17 Biologics Market, By Indication, By Value, 2022A-2030F (USD Million)
Figure 57: Germany IL-17 Biologics Market Share, By Drug, By Value, 2022 (%)
Figure 58: Germany IL-17 Biologics Market, By Drug, By Value, 2022A-2030F (USD Million)
Figure 59: United Kingdom IL-17 Biologics Market, By Value, 2022A-2030F (USD Million & CAGR)
Figure 60: United Kingdom IL-17 Biologics Market Value, By Indication, 2022 (USD Million)
Figure 61: United Kingdom IL-17 Biologics Market Share, By Indication, By Value, 2022 (%)
Figure 62: United Kingdom IL-17 Biologics Market, By Indication, By Value, 2022A-2030F (USD Million)
Figure 63: United Kingdom IL-17 Biologics Market Share, By Drug, By Value, 2022 (%)
Figure 64: United Kingdom IL-17 Biologics Market, By Drug, By Value, 2022A-2030F (USD Million)
Figure 65: France IL-17 Biologics Market, By Value, 2022A-2030F (USD Million & CAGR)
Figure 66: France IL-17 Biologics Market Value, By Indication, 2022 (USD Million)
Figure 67: France IL-17 Biologics Market Share, By Indication, By Value, 2022 (%)
Figure 68: France IL-17 Biologics Market, By Indication, By Value, 2022A-2030F (USD Million)
Figure 69: France IL-17 Biologics Market Share, By Drug, By Value, 2022 (%)
Figure 70: France IL-17 Biologics Market, By Drug, By Value, 2022A-2030F (USD Million)
Figure 71: Spain IL-17 Biologics Market, By Value, 2022A-2030F (USD Million & CAGR)
Figure 72: Spain IL-17 Biologics Market Value, By Indication, 2022 (USD Million)
Figure 73: Spain IL-17 Biologics Market Share, By Indication, By Value, 2022 (%)
Figure 74: Spain IL-17 Biologics Market, By Indication, By Value, 2022A-2030F (USD Million)
Figure 75: Spain IL-17 Biologics Market Share, By Drug, By Value, 2022 (%)
Figure 76: Spain IL-17 Biologics Market, By Drug, By Value, 2022A-2030F (USD Million)
Figure 77: Rest of Europe IL-17 Biologics Market , By Value, 2022A-2030F (USD Million & CAGR)
Figure 78: Rest of Europe IL-17 Biologics Market Value, By Indication, 2022 (USD Million)
Figure 79: Rest of Europe IL-17 Biologics Market Share, By Indication, By Value, 2022 (%)
Figure 80: Rest of Europe IL-17 Biologics Market, By Indication, By Value, 2022A-2030F (USD Million)
Figure 81: Rest of Europe IL-17 Biologics Market Share, By Drug, By Value, 2022 (%)
Figure 82: Rest of Europe IL-17 Biologics Market, By Drug, By Value, 2022A-2030F (USD Million)
Figure 83: Asia-Pacific IL-17 Biologics Market Size, By Value, 2022A-2030F (USD Million)
Figure 84: Asia-Pacific IL-17 Biologics Market Share, By Drug, 2022 (%)
Figure 85: Asia-Pacific IL-17 Biologics Market, By Psoriasis, By Value, 2022A-2030F (USD Million & CAGR)
Figure 86: Asia-Pacific IL-17 Biologics Market, By Psoriatic Arthritis, By Value, 2022A-2030F (USD Million & CAGR)
Figure 87: Asia-Pacific IL-17 Biologics Market, By Ankylosing Spondylitis, By Value, 2022A-2030F (USD Million & CAGR)
Figure 88: Asia-Pacific IL-17 Biologics Market, By Secukinumab, By Value, 2022A-2030F (USD Million & CAGR)
Figure 89: Asia-Pacific IL-17 Biologics Market, By Ixekizumab, By Value, 2022A-2030F (USD Million & CAGR)
Figure 90: Asia-Pacific IL-17 Biologics Market, By Bimekizumab, By Value, 2022A-2030F (USD Million & CAGR)
Figure 91: Asia-Pacific IL-17 Biologics Market, By Brodalumab, By Value, 2022A-2030F (USD Million & CAGR)
Figure 92: China IL-17 Biologics Market, By Value, 2022A-2030F (USD Million & CAGR)
Figure 93: China IL-17 Biologics Market Value, By Indication, 2022 (USD Million)
Figure 94: China IL-17 Biologics Market Share, By Indication, By Value, 2022 (%)
Figure 95: China IL-17 Biologics Market, By Indication, By Value, 2022A-2030F (USD Million)
Figure 96: China IL-17 Biologics Market Share, By Drug, By Value, 2022 (%)
Figure 97: China IL-17 Biologics Market, By Drug, By Value, 2022A-2030F (USD Million)
Figure 98: Japan IL-17 Biologics Market, By Value, 2022A-2030F (USD Million & CAGR)
Figure 99: Japan IL-17 Biologics Market Value, By Indication, 2022 (USD Million)
Figure 100: Japan IL-17 Biologics Market Share, By Indication, By Value, 2022 (%)
Figure 101: Japan IL-17 Biologics Market, By Indication, By Value, 2022A-2030F (USD Million)
Figure 102: Japan IL-17 Biologics Market Share, By Drug, By Value, 2022 (%)
Figure 103: Japan IL-17 Biologics Market, By Drug, By Value, 2022A-2030F (USD Million)
Figure 104: Australia IL-17 Biologics Market, By Value, 2022A-2030F (USD Million & CAGR)
Figure 105: Australia IL-17 Biologics Market Value, By Indication, 2022 (USD Million)
Figure 106: Australia IL-17 Biologics Market Share, By Indication, By Value, 2022 (%)
Figure 107: Australia IL-17 Biologics Market, By Indication, By Value, 2022A-2030F (USD Million)
Figure 108: Australia IL-17 Biologics Market Share, By Drug, By Value, 2022 (%)
Figure 109: Australia IL-17 Biologics Market, By Drug, By Value, 2022A-2030F (USD Million)
Figure 110: Rest of Asia-Pacific IL-17 Biologics Market, By Value, 2022A-2030F (USD Million & CAGR)
Figure 111: Rest of Asia-Pacific IL-17 Biologics Market Value, By Indication, 2022 (USD Million)
Figure 112: Rest of Asia-Pacific IL-17 Biologics Market Share, By Indication, By Value, 2022 (%)
Figure 113: Rest of Asia-Pacific IL-17 Biologics Market, By Indication, By Value, 2022A-2030F (USD Million)
Figure 114: Rest of Asia-Pacific IL-17 Biologics Market Share, By Drug, By Value, 2022 (%)
Figure 115: Rest of Asia-Pacific IL-17 Biologics Market, By Drug, By Value, 2022A-2030F (USD Million)
Figure 116: Global Impact of Drivers and Restraints
Figure 117: Market Share of Prominent Companies of IL-17 Biologics, 2022 (%)
Figure 118: Novartis Revenues, 2020-2022 (USD Million)
Figure 119: Novartis Revenue, By Business Segments, 2022 (%)
Figure 120: Novartis Revenue, By Geographical Segments, 2022 (%)
Figure 121: Eli Lilly and Company Revenues, 2020-2022 (USD Million)
Figure 122: Eli Lilly and Company Revenues, By Geographic Segments, 2022 (%)
Figure 123: Eli Lilly and Company Revenue, By Therapeutic Area, 2022 (%)
Figure 124: UCB Revenues, 2020-2022 (USD Million)
Figure 125: UCB, By Geographic Segments, 2022 (%)
Figure 126: UCB , By commercial products, 2022 (%)
Figure 127: AstraZeneca PLC Revenues, 2020-2022 (USD Million)
Figure 128: AstraZeneca PLC Revenues, By Geographic Segments, 2022 (%)
Figure 129: AstraZeneca PLC Revenue, By Business Segments, 2022 (%)
List of Tables
Table A1: Global Impact of Macro Economic Factors, By Region
Table A2: Pipeline development of IL-17 Biologics
Table A3: Novartis Key Company Financials, 2020-2022
Table A4: Eli Lilly and Company Key Financials, 2020-2022
Table A5: UCB Key Financials, 2020-2022
Table A6: AstraZeneca PLC Key Financials, 2020-2022
